Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Resolvin D1 promotes the targeting and clearance of necroptotic cells.

Gerlach BD, Marinello M, Heinz J, Rymut N, Sansbury BE, Riley CO, Sadhu S, Hosseini Z, Kojima Y, Tang DD, Leeper NJ, Spite M, Barroso M, Rayner KJ, Fredman G.

Cell Death Differ. 2019 Jun 20. doi: 10.1038/s41418-019-0370-1. [Epub ahead of print]

PMID:
31222041
2.

Resolving atherosclerosis and Alzheimer disease.

Fredman G.

Nat Rev Cardiol. 2019 May;16(5):259-260. doi: 10.1038/s41569-019-0182-5. No abstract available.

PMID:
30903022
3.

Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype?

Fredman G.

Front Pharmacol. 2019 Mar 7;10:205. doi: 10.3389/fphar.2019.00205. eCollection 2019. Review.

4.

Resolving inflammation and pain of sickle cell.

Fredman G.

Blood. 2019 Jan 17;133(3):190-191. doi: 10.1182/blood-2018-11-886259. No abstract available.

5.

The inflamed sputum in lower respiratory tract infection: l-lactate levels are correlated to neutrophil accumulation.

Fredman G, Kolpen M, Hertz FB, Petersen PT, Jensen AV, Baunbaek-Egelund G, Ravn P, Jensen PØ, Faurholt-Jepsen D.

APMIS. 2019 Feb;127(2):72-79. doi: 10.1111/apm.12913. Epub 2019 Jan 6.

PMID:
30614067
6.

DELineating resolution of inflammation.

Fredman G.

Nat Immunol. 2019 Jan;20(1):2-3. doi: 10.1038/s41590-018-0278-9. No abstract available.

PMID:
30538337
7.

Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.

Yurdagul A Jr, Doran AC, Cai B, Fredman G, Tabas IA.

Front Cardiovasc Med. 2018 Jan 8;4:86. doi: 10.3389/fcvm.2017.00086. eCollection 2017. Review.

8.

CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis.

Doran AC, Ozcan L, Cai B, Zheng Z, Fredman G, Rymond CC, Dorweiler B, Sluimer JC, Hsieh J, Kuriakose G, Tall AR, Tabas I.

J Clin Invest. 2017 Nov 1;127(11):4075-4089. doi: 10.1172/JCI94735. Epub 2017 Oct 3.

9.

Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.

Fredman G, Tabas I.

Am J Pathol. 2017 Jun;187(6):1211-1221. doi: 10.1016/j.ajpath.2017.01.018. Review.

10.

Pro-resolution therapeutics for cardiovascular diseases.

Heinz J, Marinello M, Fredman G.

Prostaglandins Other Lipid Mediat. 2017 Sep;132:12-16. doi: 10.1016/j.prostaglandins.2017.03.004. Epub 2017 Apr 24. Review.

PMID:
28450270
11.

Specialized pro-resolving mediators in cardiovascular diseases.

Fredman G, Spite M.

Mol Aspects Med. 2017 Dec;58:65-71. doi: 10.1016/j.mam.2017.02.003. Epub 2017 Feb 28. Review.

12.

MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.

Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, Tabas I.

J Clin Invest. 2017 Feb 1;127(2):564-568. doi: 10.1172/JCI90520. Epub 2017 Jan 9.

13.

Fine-tuning inflammation-resolution programs: focus on atherosclerosis.

Fredman G, Sadhu S, Rymut N.

Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):117-123. doi: 10.1097/MCO.0000000000000351. Review.

PMID:
27984234
14.

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.

Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I.

Nat Commun. 2016 Sep 23;7:12859. doi: 10.1038/ncomms12859.

15.

MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation.

Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G, Tabas I.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6526-31. doi: 10.1073/pnas.1524292113. Epub 2016 May 19.

16.

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

Kamaly N, Fredman G, Fojas JJ, Subramanian M, Choi WI, Zepeda K, Vilos C, Yu M, Gadde S, Wu J, Milton J, Carvalho Leitao R, Rosa Fernandes L, Hasan M, Gao H, Nguyen V, Harris J, Tabas I, Farokhzad OC.

ACS Nano. 2016 May 24;10(5):5280-92. doi: 10.1021/acsnano.6b01114. Epub 2016 Apr 28.

17.

Platelets: Context-Dependent Vascular Protectors or Mediators of Disease.

Westrick R, Fredman G; Early Career Committee.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):e25-9. doi: 10.1161/ATVBAHA.115.305898. Review. No abstract available.

18.

Supporting young people living with cancer to tell their stories in ways that make them stronger: The Beads of Life approach.

Portnoy S, Girling I, Fredman G.

Clin Child Psychol Psychiatry. 2016 Apr;21(2):255-67. doi: 10.1177/1359104515586467. Epub 2015 May 25.

PMID:
26008644
19.

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, Kuriakose G, Perretti M, Farokzhad O, Tabas I.

Sci Transl Med. 2015 Feb 18;7(275):275ra20. doi: 10.1126/scitranslmed.aaa1065. Erratum in: Sci Transl Med. 2015 Mar 4;7(277):277er2. Farokzhad, Omid [corrected to Farokhzad, Omid].

20.

Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair.

Leoni G, Neumann PA, Kamaly N, Quiros M, Nishio H, Jones HR, Sumagin R, Hilgarth RS, Alam A, Fredman G, Argyris I, Rijcken E, Kusters D, Reutelingsperger C, Perretti M, Parkos CA, Farokhzad OC, Neish AS, Nusrat A.

J Clin Invest. 2015 Mar 2;125(3):1215-27. doi: 10.1172/JCI76693. Epub 2015 Feb 9.

21.

Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway.

Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5. doi: 10.1073/pnas.1410851111. Epub 2014 Sep 22.

22.

Up close: family therapy challenges and innovations around the world.

Roberts J, Abu-Baker K, Diez Fernández C, Chong Garcia N, Fredman G, Kamya H, Martín Higarza Y, Fortes de Leff J, Messent P, Nakamura S, Torun Reid F, Sim T, Subrahmanian C, Zevallos Vega R.

Fam Process. 2014 Sep;53(3):544-76. doi: 10.1111/famp.12093. Epub 2014 Aug 7.

PMID:
25099431
23.

Inflammation and its resolution as determinants of acute coronary syndromes.

Libby P, Tabas I, Fredman G, Fisher EA.

Circ Res. 2014 Jun 6;114(12):1867-79. doi: 10.1161/CIRCRESAHA.114.302699. Review.

24.

Common therapeutic targets in cardiometabolic disease.

Fredman G, Ozcan L, Tabas I.

Sci Transl Med. 2014 Jun 4;6(239):239ps5. doi: 10.1126/scitranslmed.3008908. Review.

25.

Recent advances in the role of immunity in atherosclerosis.

Fredman G, Spite M.

Circ Res. 2013 Dec 6;113(12):e111-4. doi: 10.1161/CIRCRESAHA.113.302986. Review. No abstract available.

PMID:
24311619
26.

Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.

Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Cheung L, Fayad ZA, Langer R, Tabas I, Farokhzad OC.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6506-11. doi: 10.1073/pnas.1303377110. Epub 2013 Mar 26.

27.

Resolvin E1 and chemokine-like receptor 1 mediate bone preservation.

Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE, Gyurko R.

J Immunol. 2013 Jan 15;190(2):689-94. doi: 10.4049/jimmunol.1103688. Epub 2012 Dec 14.

28.

Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA.

Fredman G, Li Y, Dalli J, Chiang N, Serhan CN.

Sci Rep. 2012;2:639. doi: 10.1038/srep00639. Epub 2012 Sep 6.

29.

Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke.

Bazan NG, Eady TN, Khoutorova L, Atkins KD, Hong S, Lu Y, Zhang C, Jun B, Obenaus A, Fredman G, Zhu M, Winkler JW, Petasis NA, Serhan CN, Belayev L.

Exp Neurol. 2012 Jul;236(1):122-30. doi: 10.1016/j.expneurol.2012.04.007. Epub 2012 Apr 19.

30.

Infection regulates pro-resolving mediators that lower antibiotic requirements.

Chiang N, Fredman G, Bäckhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN.

Nature. 2012 Apr 25;484(7395):524-8. doi: 10.1038/nature11042.

31.

Resolvin E2 formation and impact in inflammation resolution.

Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN.

J Immunol. 2012 May 1;188(9):4527-34. doi: 10.4049/jimmunol.1103652. Epub 2012 Mar 26.

32.

Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.

Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN.

Am J Pathol. 2012 May;180(5):2018-27. doi: 10.1016/j.ajpath.2012.01.028. Epub 2012 Mar 23.

33.

Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1.

Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE.

PLoS One. 2011;6(9):e24422. doi: 10.1371/journal.pone.0024422. Epub 2011 Sep 14.

34.

Novel proresolving aspirin-triggered DHA pathway.

Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M, Winkler JW, Petasis NA.

Chem Biol. 2011 Aug 26;18(8):976-87. doi: 10.1016/j.chembiol.2011.06.008.

35.

Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals.

Yang R, Fredman G, Krishnamoorthy S, Agrawal N, Irimia D, Piomelli D, Serhan CN.

J Biol Chem. 2011 Sep 9;286(36):31532-41. doi: 10.1074/jbc.M111.237990. Epub 2011 Jul 12.

36.

Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution.

Fredman G, Serhan CN.

Biochem J. 2011 Jul 15;437(2):185-97. doi: 10.1042/BJ20110327.

37.

MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits.

Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN.

FASEB J. 2011 Feb;25(2):544-60. doi: 10.1096/fj.10-169599. Epub 2010 Oct 18.

38.

Resolvin E1 regulates adenosine diphosphate activation of human platelets.

Fredman G, Van Dyke TE, Serhan CN.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):2005-13. doi: 10.1161/ATVBAHA.110.209908. Epub 2010 Aug 11.

39.

Diabetes-induced oxidative stress is mediated by Ca2+-independent phospholipase A2 in neutrophils.

Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H, Iwata T, Yagi M, Hasturk H, Van Dyke TE.

J Immunol. 2010 Feb 1;184(3):1507-15. doi: 10.4049/jimmunol.0901219. Epub 2010 Jan 6.

40.

Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, Cheng G, von Andrian UH, Serhan CN.

Blood. 2008 Aug 1;112(3):848-55. doi: 10.1182/blood-2007-11-122598. Epub 2008 May 14.

41.

Anesthetics impact the resolution of inflammation.

Chiang N, Schwab JM, Fredman G, Kasuga K, Gelman S, Serhan CN.

PLoS One. 2008 Apr 2;3(4):e1879. doi: 10.1371/journal.pone.0001879.

42.

Reflecting teams with children: the bear necessities.

Fredman G, Christie D, Bear N.

Clin Child Psychol Psychiatry. 2007 Apr;12(2):211-22.

PMID:
17533936
43.

Resolvin D series and protectin D1 mitigate acute kidney injury.

Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV.

J Immunol. 2006 Nov 1;177(9):5902-11.

44.

Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression.

Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, Luster AD, Serhan CN.

Nat Immunol. 2006 Nov;7(11):1209-16. Epub 2006 Oct 1.

45.

The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering.

Ariel A, Li PL, Wang W, Tang WX, Fredman G, Hong S, Gotlinger KH, Serhan CN.

J Biol Chem. 2005 Dec 30;280(52):43079-86. Epub 2005 Oct 10.

46.

The challenge of deliberate self-harm by young adolescents.

Reder P, Lucey C, Fredman G.

J Adolesc. 1991 Jun;14(2):135-48.

PMID:
1918515
47.

The social environmental correlates of reading ability.

Stevenson J, Fredman G.

J Child Psychol Psychiatry. 1990 Jul;31(5):681-98.

PMID:
2398114
48.

A twin study of genetic influences on reading and spelling ability and disability.

Stevenson J, Graham P, Fredman G, McLoughlin V.

J Child Psychol Psychiatry. 1987 Mar;28(2):229-47.

PMID:
3584294

Supplemental Content

Loading ...
Support Center